Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia.
compulsivity
elevated plus maze test
fear conditioning
forced swimming test
glutamatergic modulators
marble burying test
schedule-induced polydipsia
Journal
Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
01
2019
accepted:
23
04
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
Compulsive behavior is observed in several neuropsychiatric disorders such as obsessive-compulsive disorder (OCD), anxiety, depression, phobia, and schizophrenia. Thus, compulsivity has been proposed as a transdiagnostic symptom with a highly variable pharmacological treatment. Recent evidence shows that glutamate pharmacotherapy may be of benefit in impaired inhibitory control. The purpose of the present study was: first, to test the comorbidity between compulsivity and other neuropsychiatric symptoms on different preclinical behavioral models; second, to assess the therapeutic potential of different glutamate modulators in a preclinical model of compulsivity. Long Evans rats were selected as either high (HD) or low (LD) drinkers corresponding with their water intake in schedule-induced polydipsia (SIP). We assessed compulsivity in LD and HD rats by marble burying test (MBT), depression by forced swimming test (FST), anxiety by elevated plus maze (EPM) and fear behavior by fear conditioning (FC) test. After that, we measured the effects of acute administration (i.p.) of glutamatergic drugs: N-Acetylcysteine (NAC; 25, 50, 100 and 200 mg/kg), memantine (3.1 and 6.2 mg/kg) and lamotrigine (15 and 30 mg/kg) on compulsive drinking on SIP. The results obtained showed a relation between high compulsive drinking on SIP and a higher number of marbles partially buried in MBT, as well as a higher percentage of freezing on the retrieval day of FC test. We did not detect any significant differences between LD and HD rats in FST, nor in EPM. The psychopharmacological study of glutamatergic drugs revealed that memantine and lamotrigine, at all doses tested, decreased compulsive water consumption in HD rats compared to LD rats on SIP. NAC did not produce any significant effect on SIP. These results indicate that the symptom clusters of different forms of compulsivity and phobia might be found in the compulsive phenotype of HD rats selected by SIP. The effects of memantine and lamotrigine in HD rats point towards a dysregulation in the glutamatergic signaling as a possible underlying mechanism in the vulnerability to compulsive behavior on SIP. Further studies on SIP, could help to elucidate the therapeutic role of glutamatergic drugs as a pharmacological strategy on compulsive spectrum disorders.
Identifiants
pubmed: 31133835
doi: 10.3389/fnbeh.2019.00100
pmc: PMC6514533
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100Références
Neuropharmacology. 2000 Aug 23;39(11):2139-46
pubmed: 10963757
Behav Brain Res. 2001 Aug 27;123(1):77-87
pubmed: 11377731
Semin Clin Neuropsychiatry. 2001 Jul;6(3):155-66
pubmed: 11447567
Schizophr Res. 2002 Oct 1;57(2-3):293-301
pubmed: 12223261
N Engl J Med. 2003 Apr 3;348(14):1333-41
pubmed: 12672860
Nat Neurosci. 2003 Jul;6(7):743-9
pubmed: 12778052
Epilepsy Res. 1992 Nov;13(2):107-12
pubmed: 1334455
Science. 1961 Jan 20;133(3447):195-6
pubmed: 13698026
Ann N Y Acad Sci. 2003 Nov;1003:349-51
pubmed: 14684458
Pharmacol Biochem Behav. 2004 Jan;77(1):69-75
pubmed: 14724043
Int J Neuropsychopharmacol. 2005 Mar;8(1):107-29
pubmed: 15450126
Int J Dev Neurosci. 2004 Nov;22(7):565-70
pubmed: 15465287
Eur Neuropsychopharmacol. 2005 Jan;15(1):119-30
pubmed: 15572281
Behav Neurosci. 1992 Apr;106(2):274-85
pubmed: 1590953
J Neurosci. 2005 Jul 6;25(27):6389-93
pubmed: 16000629
Psychopharmacology (Berl). 2006 Jan;184(2):254-6
pubmed: 16374600
J Clin Psychiatry. 2005 Nov;66(11):1492-3
pubmed: 16420092
Psychopharmacology (Berl). 2006 Sep;187(4):424-34
pubmed: 16835770
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
Curr Psychiatry Rep. 2007 Jun;9(3):236-41
pubmed: 17521521
Neurosci Biobehav Rev. 2008;32(3):525-49
pubmed: 18061263
Psychopharmacology (Berl). 2008 Apr;197(3):487-98
pubmed: 18322677
Pharmacol Biochem Behav. 1991 Oct;40(2):311-5
pubmed: 1839567
Eur J Pharmacol. 2008 May 31;586(1-3):164-70
pubmed: 18423440
Curr Protoc Neurosci. 2008 Apr;Chapter 9:Unit 9.27
pubmed: 18428677
Behav Brain Res. 2008 Aug 5;191(1):49-54
pubmed: 18433891
Biol Psychiatry. 2009 Sep 1;66(5):522-6
pubmed: 19545857
Exp Clin Psychopharmacol. 2009 Jun;17(3):191-7
pubmed: 19586234
J Alzheimers Dis. 2009;18(3):509-13
pubmed: 19661628
Phytomedicine. 2010 Mar;17(3-4):274-8
pubmed: 19674881
Neuropsychopharmacology. 2010 Feb;35(3):591-604
pubmed: 19940844
Brain Res Bull. 2010 Apr 5;81(6):585-9
pubmed: 19954760
Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205
pubmed: 20047711
J Clin Psychopharmacol. 2010 Feb;30(1):34-9
pubmed: 20075645
Neurotox Res. 2011 Jan;19(1):128-37
pubmed: 20087798
J Psychopharmacol. 2010 Dec;24(12):1772-8
pubmed: 20123938
Psychopharmacology (Berl). 2010 May;210(1):13-24
pubmed: 20238210
Neurochem Int. 2010 Sep;57(2):168-76
pubmed: 20493916
Neurosci Bull. 2010 Aug;26(4):327-37
pubmed: 20651815
Behav Brain Res. 2011 Feb 2;217(1):195-201
pubmed: 20974181
Neuroscience. 2011 Mar 10;176:336-48
pubmed: 21193020
Curr Opin Neurobiol. 2011 Dec;21(6):842-8
pubmed: 21605970
Sci Transl Med. 2011 Sep 28;3(102):102mr2
pubmed: 21957170
Pharmacol Ther. 2011 Dec;132(3):314-32
pubmed: 21963369
Psychopharmacology (Berl). 2012 Jan;219(2):401-10
pubmed: 22101355
Psychopharmacology (Berl). 2012 Jan;219(2):647-59
pubmed: 22113447
Psychopharmacology (Berl). 2012 Jan;219(2):661-72
pubmed: 22113449
Trends Cogn Sci. 2012 Jan;16(1):43-51
pubmed: 22138231
J Psychopharmacol. 2012 Nov;26(11):1456-62
pubmed: 22351381
Rev Neurosci. 2012;23(5-6):645-57
pubmed: 23006899
J Psychiatr Res. 2013 Feb;47(2):175-80
pubmed: 23063327
J Clin Psychopharmacol. 2012 Dec;32(6):797-803
pubmed: 23131885
Neuropsychopharmacology. 2013 Apr;38(5):701-14
pubmed: 23232445
Eur Neuropsychopharmacol. 2013 Dec;23(12):1769-78
pubmed: 23434291
Psychopharmacology (Berl). 2013 Aug;228(4):633-40
pubmed: 23525525
Int J Neuropsychopharmacol. 2013 Sep;16(8):1809-18
pubmed: 23551979
Psychiatry Res. 2013 Dec 30;210(3):679-83
pubmed: 23810384
Psychopharmacology (Berl). 2014 May;231(9):2001-8
pubmed: 24241687
Compr Psychiatry. 2014 Apr;55(3):588-97
pubmed: 24374170
Annu Rev Pharmacol Toxicol. 2014;54:119-39
pubmed: 24392693
J Vis Exp. 2013 Dec 24;(82):50978
pubmed: 24429507
CNS Spectr. 2014 Feb;19(1):69-89
pubmed: 24512640
Front Neural Circuits. 2014 Jun 11;8:58
pubmed: 24966814
Int J Neuropsychopharmacol. 2014 Nov;17(11):1905-10
pubmed: 25025529
Addict Biol. 2015 Sep;20(5):890-901
pubmed: 25138717
Indian J Psychol Med. 2015 Apr-Jun;37(2):154-8
pubmed: 25969599
J Neurochem. 2015 Sep;134(6):1081-90
pubmed: 26112331
Behav Brain Res. 2015 Oct 1;292:370-80
pubmed: 26142783
Mol Psychiatry. 2016 Apr;21(4):491-9
pubmed: 26370145
Ann Clin Psychiatry. 2015 Nov;27(4):261-6
pubmed: 26554367
Front Pharmacol. 2015 Oct 23;6:242
pubmed: 26557090
J Affect Disord. 2016 Jan 15;190:508-516
pubmed: 26561941
J Clin Psychiatry. 2015 Dec;76(12):1668-74
pubmed: 26717526
J Clin Pharm Ther. 2016 Apr;41(2):214-9
pubmed: 26931055
Int J Obes (Lond). 2016 Jul;40(7):1183-6
pubmed: 26975440
Psychiatry Res. 2016 May 30;239:68-71
pubmed: 27137963
J Affect Disord. 2016 Oct;203:241-247
pubmed: 27310102
Iran J Psychiatry. 2016 Apr;11(2):104-14
pubmed: 27437007
Asian J Psychiatr. 2016 Aug;22:69-73
pubmed: 27520897
Schizophr Bull. 2017 Jul 1;43(4):778-787
pubmed: 27872269
Front Behav Neurosci. 2016 Nov 09;10:215
pubmed: 27881956
Physiol Behav. 2017 Feb 1;169:234-244
pubmed: 27939364
Pharmacol Biochem Behav. 1989 Apr;32(4):949-55
pubmed: 2798543
Ann Clin Psychiatry. 2017 Feb;29(1):17-26
pubmed: 28207912
Curr Neuropharmacol. 2017;15(7):977-995
pubmed: 28322166
Psychol Med. 2017 Jul;47(9):1528-1548
pubmed: 28343453
Addict Biol. 2018 Mar;23(2):643-652
pubmed: 28557352
Front Psychiatry. 2017 May 22;8:89
pubmed: 28588509
Brain Res. 1985 Aug 12;340(2):378-83
pubmed: 2862960
J Neurosci Methods. 1985 Aug;14(3):149-67
pubmed: 2864480
Pharmacopsychiatry. 2018 Nov;51(6):229-242
pubmed: 28950396
Int J Neuropsychopharmacol. 2018 Jan 1;21(1):42-58
pubmed: 29036632
J Affect Disord. 2018 Feb;227:633-642
pubmed: 29174736
Acta Neurobiol Exp (Wars). 2017;77(3):254-260
pubmed: 29182616
Mol Psychiatry. 2018 Nov;23(11):2122-2132
pubmed: 29298989
Psychopharmacology (Berl). 2018 Feb;235(2):419-432
pubmed: 29313138
Neuropharmacology. 2018 Jun;135:487-495
pubmed: 29604294
Behav Processes. 2018 Dec;157:590-600
pubmed: 29694852
Genes Brain Behav. 2019 Mar;18(3):e12489
pubmed: 29877027
J Clin Psychiatry. 1986 Apr;47 Suppl:16-22
pubmed: 3007443
Neuropharmacology. 2018 Dec;143:10-19
pubmed: 30201211
Dtsch Arztebl Int. 2018 Sep 14;155(37):611-620
pubmed: 30282583
Psychol Rep. 1987 Jun;60(3 Pt 1):803-7
pubmed: 3615724
Nature. 1977 Apr 21;266(5604):730-2
pubmed: 559941
J Exp Anal Behav. 1966 Jan;9(1):37-9
pubmed: 5903958
Pflugers Arch. 1995 Jul;430(3):437-46
pubmed: 7491269
Neurochem Res. 1995 Feb;20(2):159-69
pubmed: 7783840
Psychopharmacology (Berl). 1993;113(2):250-6
pubmed: 7855190
J Pharmacol Exp Ther. 1994 Nov;271(2):638-50
pubmed: 7965779
Biol Psychiatry. 1994 Mar 15;35(6):408-19
pubmed: 8018788
Neuropsychopharmacology. 1998 Jun;18(6):431-43
pubmed: 9571652
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15003-7
pubmed: 9844005
Pharmacol Rev. 1998 Dec;50(4):597-664
pubmed: 9860805
Behav Neurosci. 1998 Dec;112(6):1475-85
pubmed: 9926830